Mr. Xu Zhi Bin ("Mr. Xu") is the Executive Chairman of our Group and he was appointed as our Chairman on 19 November 2012. Mr. Xu has over 21 years of experience in the pharmaceutical industry specializing in sales and marketing. He is responsible for the Group's operations in strategic planning, corporate daily management and business development. Between 2005 and 2012, he was the General Manager of Beijing Jiuzhou Jikang Pharmaceutical Co., Ltd., where he was responsible for overall strategic planning and direction of the company, including the day-to-day management, financial planning and budgeting, sales and marketing, product development and management, and long-term investment strategy of the company. Prior to that between 2000 and 2005, he was the Director of Sales of Hainan Tongyong Sanyang Pharmaceutical Co., Ltd., where he was responsible for all sales and marketing activities of the company. Between 1996 and 2000, he was the Sales Manager of Shenzhen Jianhua Pharmaceutical Co., Ltd. Mr. Xu graduated from the Capital University of Medical Sciences in 1996 with a Bachelor's Degree majoring in clinical medicine.
Ms. Li Tak Tai Leada ("Ms. Li") was appointed as our Non-Executive Director on 24 August 2009. She is currently the Managing Director of Grand International Investment (China) Co. Ltd. From December 2006 to August 2015, Ms. Li was the Chief Financial Officer of China Precision Steel, Inc., a company that is engaged in high value-add steel processing and listed on the Nasdaq Capital Market, where she was responsible for overseeing the financial, accounting and administrative matters of the Company. From December 2006 to August 2009, Ms. Li was our part time investor relations consultant where she was responsible for the Company's investor relations and corporate communication matters. Prior to that, from June 2004 to November 2006, Ms. Li was Assistant to Chairman of our Company, in charge of the Group's Initial Public Offering on the SGX-ST and investor relations. From November 2003 to May 2004, Ms. Li was an audit assistant at KPMG, Hong Kong, where she assisted her seniors in carrying out commercial due diligence of target companies located in the PRC. Prior to that, from January 2002 to September 2002, Ms. Li was an Investment Analyst at Suez Asia Holdings (HK) Limited, where she assisted with the research work for various private equity deals. Ms. Li holds a Bachelor of Commerce Degree with dual major in Accounting and Finance from the University of Melbourne in Australia and a Master of Science Degree in Accounting and Finance from the Napier University in the United Kingdom.
Mr. Ng Poh Khoon ("Mr. Ng") was appointed as our Independent Director on 27 September 2005 and was appointed as Lead Independent Director on 26 March 2015. He is currently the Project Director with Guangdong Chengde Financial Advisory Co., Ltd and a member of Financial Advisory Committee with the Entrepreneur Capital Management Association of Guangdong Province. Mr. Ng had over 20 years of experiences in auditing, financial management, sales & business development, IR, fund raising and M&A activities. Mr. Ng is currently the Independent Director and the Chairman of the Audit Committee of Nutryfarm International Limited, a company listed on the mainboard of SGX-ST. Mr. Ng is a Chartered Accountant and a member of the Institute of Singapore Chartered Accountants and Singapore Institute of Directors. Mr. Ng is also a fellow member of the Association of Chartered Certified Accountants, UK.
Mr. Meng Tao ("Mr. Meng") was appointed as our Independent Director on 1 January 2015. He is currently the International Trade Consultant of Beijing Jiashi Hongrun Pharmaceutical Co., Ltd. Mr. Meng has over 17 years of experience in the pharmaceutical industry. He was the International Trade Consultant of Haerbin Medisan Pharmaceutical Co., Ltd from September 2003 to October 2013. Prior to that, from July 2002 to August 2003, Mr. Meng was the Japanese department assistant sales director of Su Zhou HaoLiShi Cable Assembly Co., Ltd. From June 2000 to June 2002, Mr. Meng was the International Trade Sales Manager of Beijing Silver Sea Star Ltd. Prior to that, he was the International Trade Sales of Hainan Tongyong Sanyang Pharmaceutical Co., Ltd from June 1997 to May 2000. Mr. Meng graduated from TOKYO COMMUNICATION ARTS in 1996 majoring in International Relations.
Mr. Wang Qi ("Mr. Wang") was appointed as our Director on 1 March 2017. Mr. Wang has over 20 years of experience in the pharmaceutical industry specializing in new drug research and development. Prior to joining our Group, from 2001 to 2016, Mr. Wang was the General Manager of Beijing AnKangJiaHe Pharmaceutical Co., Ltd, responsible for the daily operations of the company. From 1996 to 2001, where he was the director of research and development of Bei Jing YongAn Pharmaceutical Co., Ltd, where he was responsible for investigation and research before project approval. Prior to that between 1990 to 1996, he was Deputy Director of the technical department of China Information Technology Development Co., Ltd. In 1990, Mr. Wang graduated from Bei Hang University with a Bachelor's Degree majoring in Computer Application.